Skip to content

Urdu Translation of Revised High-Level Mobility Assessment Tool (HiMAT) in Healthy Children

Urdu Translation of Psychometric Properties Analysis of Revised High-Level Mobility Assessment Tool (HiMAT) in Healthy Children

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06986720
Enrollment
80
Registered
2025-05-23
Start date
2025-05-12
Completion date
2025-07-16
Last updated
2025-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Children

Keywords

revised HiMAT, Urdu translation, validation, mobility

Brief summary

The ability to move with ease is labelled as mobility. Limitations in mobility are frequent, recovery of these skills is crucial for physical performance which gives children valuable social possibilities and has long-term advantages for their physical and mental health. The high-level mobility assessment tool (HiMAT) is a unidimensional performance to measure the degree of high-level mobility in traumatic brain injury patients. The revised HiMAT has been utilised recently in paediatric populations to assess clinical trial outcomes and measure high-level motor skills. Urdu translation of revised HiMAT will be executed by using forward backwards translation method. Two bilingual translators fluent in both Urdu and English languages will facilitate the researcher in the translation of the tool. This final translated version will be then tested for validity and reliability on all participants of the study. The psychometric properties of the tool will be assessed including reliability, internal consistency, and item discrimination.

Detailed description

Following steps will be followed for translation: 1. Forward Translation: Two independent translators who spoke Urdu as their native language will conduct initial translation into Urdu (U-HiMAT). 2. Synthesis: In this step both translated versions (U1 & U2) will be synthesized to obtain a common translated version of U-HiMAT. Full Urdu version of scale will be completed. 3. Backward Translation: Urdu translated version will be translated back into English by a different team consisting of professional independent bilingual translators. 4. Expert Committee: Expert committees consisting of pediatric physical therapists and pediatric clinical practitioners will evaluate and review the difference between a translated version and an original draft. They will create a pre final version for field testing. 5. Pre-Final Version Testing: Pre-final Urdu and English version of scale will be tested on patients. Expert panel will review the findings from this process. After completion of translation process, psychometric properties of the tool will be analysed.

Interventions

None listed

Sponsors

Riphah International University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
5 Years to 12 Years
Healthy volunteers
Yes

Inclusion criteria

* Children with age group 5-12 years * No condition affecting mobility of children * Able to understand and follow instruction. * Can speak & understand language

Exclusion criteria

* Children with visual impairments. * Children with conditions affecting their mobility. * Children with any history of surgery in the past one year. * Children with any cardiorespiratory comorbidities. * Children with muscle strain, ligament sprain or joint laxity in lower extremities. * Cognition less than 20 on Mini Mental State Examination (MMSE). * Children with any history of any foot deformity

Design outcomes

Primary

MeasureTime frameDescription
Revised High Level Mobility Assessment Tool (HiMAT)6 monthsHiMAT is a single dimensional inspection of high-level movability for those suffering from TBI. The revised HiMAT comprises of 8 items that evaluate (1) walk forward, (2) walk backwards, (3) walk on toes and (4) walk over obstacle, (5) running, (6) skipping, (7) hopping, and (8) bounding. HiMAT has also been used to assess mobility in children with healthy conditions or suffering from any neurological disorder

Countries

Pakistan

Contacts

Primary ContactImran Amjad, PhD
imran.amjad@riphah.edu.pk+9233224390125
Backup ContactMuhammad Asif Javed, MS
a.javed@riphah.edu.pk+923224209422

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026